Marsh & Mclennan (MMC) has disclosed a new risk, in the Brand / Reputation category.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Marsh & McLennan faces significant risks associated with the U.S. healthcare industry, primarily due to the complex and evolving regulatory landscape. Their subsidiaries, Mercer, MMA, and MMB, provide services like plan design and insurance brokering, which are vulnerable to frequent legislative changes. These changes could disincentivize employer-sponsored health insurance or alter compensation structures, impacting revenue from consulting and broking services. Additionally, negative publicity from governmental investigations or media scrutiny could harm their reputation and invite further regulatory challenges.
The average MMC stock price target is $235.15, implying 3.14% upside potential.
To learn more about Marsh & Mclennan’s risk factors, click here.
